Prospective randomized evaluation of stentless vs. stented aortic biologic prosthetic valves in the elderly at five years
|
|
- Kenneth Waters
- 6 years ago
- Views:
Transcription
1 doi: /icvts Interactive CardioVascular and Thoracic Surgery 8 (009) Follow-up papers - Valves Prospective randomized evaluation of stentless vs. stented aortic biologic prosthetic valves in the elderly at five years Petar S. Risteski*, Sven Martens, Amin Rouhollahpour, Gerhard Wimmer-Greinecker, Anton Moritz, Mirko Doss Department of Thoracic and Cardiovascular Surgery, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany Received 6 April 008; received in revised form 1 August 008; accepted 13 August 008 Abstract Objectives: Randomized trials comparing stentless to stented bioprostheses for aortic valve replacement in elderly are scarce. The aim of this study was early and mid-term evaluation of these bioprostheses, with regards to clinical outcome and hemodynamic performance. Methods: Between September 1999 and January 001, 40 patients with aortic stenosis, over the age of 75 years, were randomly assigned to receive either the stented Perimount (ns0) or the stentless Prima Plus (ns0) bioprosthesis. Clinical outcomes, left ventricular mass regression, effective orifice area, ejection fraction and mean gradients were evaluated at discharge, six months, one year and five years after surgery. Results: At five years, there were 5y0 (5%) deaths in the stentless group and 6y0 (30%) deaths in the stented group (all non-valve-related). There was one case of endocarditis in each group, early postoperatively. Overall, a significant decrease in left ventricular mass was found five years postoperatively. However, there was no significant difference in the rate and completeness of LVmass regression between the groups (LV mass index 114"34.1 vs. 10"7.). Furthermore, hemodynamic performance of the valves (mean gradient of 9.9"4.8 mmhg vs. 10."4. mmhg) did not differ significantly between the groups. Conclusions: At five years, stentless valves were not superior to the stented valves, with regards to hemodynamic performance, regression of left ventricular mass and clinical outcome. 009 Published by European Association for Cardio-Thoracic Surgery. All rights reserved. Keywords: Aortic valve replacement; Heart valve; Bioprosthesis; Stentless valve 1. Introduction Aortic valve replacement (AVR) with biologic prosthesis is the only definitive treatment for patients older than 65 years with severe aortic valve stenosis. Despite excellent early postoperative outcome, long-term survival is not satisfactory. Reported survival rates in all age groups range between 50% and 66% w1, x and further decrease to 18% at 15 years in patients older than 75 years of age w3x. Several studies have related these poor results after AVR with the incomplete regression of the left ventricular hypertrophy w4, 5x. Left ventricular hypertrophy (LVH), a known complication of aortic stenosis, has been strongly associated with increased risk of sudden death, congestive heart failure, stroke, myocardial infarction and overall cardiovascular mortality. Incomplete regression of the LVH in patients undergoing AVR has been linked to the obstructive nature of the valve sewing ring and stent, or to patient prosthesis mismatch, which are being held responsible for persistently elevated transvalvular gradients. In the late 1980s, stentless valves were introduced with the goal of maximizing the effective orifice area for flow by eliminating the valvular stent and sewing ring, therefore *Corresponding author. Tel.: q ; fax: q address: docpsr@yahoo.com (P.S. Risteski). 009 Published by European Association for Cardio-Thoracic Surgery facilitating faster and more complete regression of LVH. Over the next decade, several groups have published their initial results; many of them indicating faster and more complete regression of left ventricular mass after stentless as compared with the stented AVR w6, 7x. However, these advantages have been obtained in the setting of nonrandomized trials. We therefore set forth to determine, if we could measure these early and mid-term postoperative improvements in older patients receiving a stentless versus a stented bioprosthetic aortic valve, in a prospective randomized setting.. Materials and methods Between September 1999 and January 001, 40 consecutive patients with severe aortic valve stenosis, older than 75 years, were eligible for inclusion in this prospective randomized trial. Patients were randomized to receive either the Carpentier Edwards Perimount (Edwards Life Sciences Inc, Irvine, CA), second-generation pericardial stented biologic prosthesis or the Prima Plus, porcine stentless biologic prosthesis (Edwards Life Sciences Inc, Irvine, CA). Prior to inclusion in this study, all patients provided written informed consent. This consent form was approved by the ethical committee of our institution.
2 450 P.S. Risteski et al. / Interactive CardioVascular and Thoracic Surgery 8 (009) Inclusion and exclusion criteria Eligible patients included those with isolated aortic valve stenosis (maximum transvalvular gradient 50 mmhg or aortic valve area -0.8 cm ) in which preoperative evaluation indicated the need for an isolated AVR. Only patients expected to survive the surgery and expected to be available to return for all follow-up examinations were included in the study. Patients who specifically chose to have a mechanical valve substitute were not suitable for enrolment. Patients that required repair or replacement of an additional heart valve and those that had prior implantation of a bioprosthetic, mechanical valve or annuloplasty device were excluded from the study. Other exclusion criteria included subaortic stenosis requiring septal resection, active endocarditis, emergency operation and history of myocardial infarction. Intraoperatively, patients were excluded from the study if their aortic root and surrounding tissues had severe calcifications that could not be completely removed surgically and if their valve anatomy indicated an abnormally dilated aortic root or would require excessive trimming of the bioprosthesis... Echocardiography Preoperative and all postoperative echocardiographic studies were performed by two experienced operators using a single echo machine (Vingmed System 5, GE Medical Systems, Wisconsin, USA). All data collected were entered in a central database. In addition to the standard imaging views, preoperative echocardiographic assessments also included the measurement of the diameter of the annulus and the size of the native aorta at the level of the sinotubular junction. We found this necessary in order to identify a possible mismatch between the annulus and the sinotubular junction, which in turn would make the patients unsuitable for the implantation of a stentless valve. Left ventricular mass index (LVMI) was calculated using the formula postulated by Devereux and Reichek, as follows: w 3 LVMI (gym )s(1.05= (EDDqPWTdqIVSTd) EDD 3x 13.6)yBSA where the EDD is the LV end-diastolic diameter (cm), the PWTd is the LV postero-lateral diastolic wall thickness (cm), the IVSTd is the interventricular septum diastolic thickness (cm), and the BSA is the body surface area of the patient w8x..3. Surgical technique All operations were performed by four senior surgeons. Intraoperatively, all patients had retrograde cold blood cardioplegia and carbon dioxide insufflation into the operative field at a rate of lymin for optimal organ protection. The aortic valve was approached through a hockey stick aortotomy. After complete resection of the native aortic valve and debridement of the aortic annulus, accurate sizing was carried out using the respective Carpentier Edwards sizers for the Prima Plus stentless and the Perimount stented valves. The Prima Plus stentless valves were implanted in the subcoronary position. The commissures were positioned 108 apart, with the muscular shelf corresponding to the right coronary sinus. Care was taken to suture the base of the valve subannularly, to ensure that the coaptation line of the leaflets was at the height of the native annulus. Single interrupted unpledgeted 4-0 braided polyester sutures were used for the proximal end, and the rims of the valve commissures were sutured to the native aorta using 4-0 polypropylene running sutures. For the Carpentier Edwards Perimount stented valve implantation, interrupted mattressed pledgeted -0 braided polyester sutures were placed circumferentially from below the annulus. The valves were implanted in the supra-annular position, with the valvular stent positioned so as not to interfere with the coronary ostia..4. Anticoagulation regime Patients in both groups underwent the same anticoagulation regime postoperatively. It included subcutaneous low molecular heparin for the first days and parallel oral anticoagulation with vitamin K antagonists. As soon as the International Normalized Ratio (INR) levels reached the therapeutic range of.5 3.5, heparin was stopped. Oral anticoagulation was continued for three months. The INR levels were monitored by the patient s general practitioner. After three months oral anticoagulation was terminated..5. Follow-up Follow-up examinations were scheduled for discharge from the hospital, at 6, 1 months and 5 years following the operation. All patients had evaluation of their clinical status including New York Heart Association (NYHA) classification, blood analysis including signs of hemolysis and coagulation profile, occurrence of early and late complications and echocardiographic data. Follow-up was 100% complete. We focused our emphasis on the evaluation of left ventricular (LV) mass regression. Both completeness and rate of LV mass regression were assessed. Additional endpoints were changes in LV function and hemodynamics including effective orifice area (EOA) and changes in postoperative transvalvular gradients..6. Statistical analysis Data were compiled and analyzed using Microsoft Access, Microsoft Excel (Redmond, WA) and Stat view (Cary, NC). The baseline characteristics and hospital outcomes for the two groups were compared using x or Fisher s exact test for categorical data and unpaired t-tests for continuous variables. Results, unless otherwise indicated, are reported as mean"s.d. in text and tables. Statistical significance was defined as a P-value of Results All preoperative clinical characteristics including age, gender, body surface area, hypertension, NYHA functional
3 P.S. Risteski et al. / Interactive CardioVascular and Thoracic Surgery 8 (009) Table 1 Preoperative patient characteristics Perimount (ns0) Prima Plus (ns0) P Male Mean age (years) 79"4.3 78" BSA (m ) 1.85" " Hypertension (mmhg) Atrial fibrillation Mean gradient (mmhg) 50.9" " IVS thickness (mm) 19.1" " LVW thickness (mm) 19.8" " LVEDD (mm) 46"3.0 48" LVESD (mm) 35" 3"3 0.8 LV EF (%) 66.6" " NYHA Class III IV BSA, body surface area; IVS, interventricular septum; LVW, left ventricular wall; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LV EF, left ventricular ejection fraction; NYHA, New York Heart Association. class as well as the echocardiographic parameters were comparable between the two groups (Table 1). The intraoperative outcomes as well as early and late morbidity and mortality are summarized in Table. The aortic cross-clamp and cardiopulmonary times were significantly longer in the group receiving stentless biologic prosthesis, however, without association to excessive morbidity and mortality in this group. In both groups, for any given annular diameter, a slightly larger valve prosthesis was implanted, averaging 1.9 mm in the Perimount group and 1.6 mm in the Prima Plus group. The cumulative rates of valve- and procedure-related complications were low and similar in both groups. Early and late mortality included two and three patients in the Perimount group and none and six patients in the Prima Plus group, respectively. All deaths were not related to the valve. All patients displayed continuous clinical improvement after the operation; at five years, all of the survivors were in New York Heart Association class I or II. Mean transvalvular gradients (Fig. 1a) have remained consistently low throughout the follow-up with neither clinical nor statistical relevance in the differences between the groups at any of the given time points. Also noted was the lack of significant difference in the follow-up values of the effective orifice areas (Fig. 1b) of both prostheses, although a tendency toward increase of the same in both groups was obvious early in follow-up (at 1 months with regards to 6 months) only to disappear at the 5-year followup examination. The left ventricular ejection fraction (Fig. 1c) did not change over the time of follow-up. At 6 and 1 months, as well as at 5 years it did not differ between the groups. The left ventricular mass index (LVMI, Fig. 1d) did display a continuous rate of decrease in the first years after the surgery; however, this tendency was lost after the first year as the mean LVMI at 5 years was almost the same to that at 1 months. Finally, the index failed to reach the normal range in both groups. At all time points, the difference between the groups did not reach statistical significance. 4. Discussion Stentless aortic valve prostheses for AVR were introduced almost two decades ago with the aim to provide a superior hemodynamic profile and eventually account for improved survival in older patients. Several retrospective studies in the late 1990s have depicted a faster and more complete regression of LV hypertrophy in patients undergoing stentless AVR. Del Rizzo and co-workers have shown a survival benefit for stentless over stented valves, with nearly a 5- fold greater probability of death at 5 years in patients younger than 60 years of age who received a stented valve prosthesis w9x. With respect to the current literature on this issue, older patients have rarely been a subject of research in comparing stentless with stented AVR. Several groups, as well as ours w10x, have initiated prospective randomized trials to compare these two types of biologic valves. Motivated by the lack of available literature on this topic in elderly, we focused on octogenarians, over 75 years of age and looked on the effects of the specific valve substitutes primarily upon the regression of the LVH as well as upon the hemodynamics and clinical outcome. Table Intraoperative outcomes, early and late morbidity and mortality Perimount (ns0) Prima Plus (ns0) P Cross-clamp time (min) 79"17 108" CPB time (min) 105"3 130"7 0.0 Implantation technique Supra-annular Subcoronary Prosthesis size (mm) Prosthesis oversizing (mm) 1.9" " Permanent neurologic deficit 1 (5%) 1 (5%) 0.9 Anticoagulation-related hemorrhage 1 (5%) Prosthetic valve thrombosis 0 0 Paravalvular leak 0 0 Structural valve deterioration 0 0 Reoperation for early prosthetic valve endocarditis 1 (5%) 1 (5%) 0.9 Early mortality (10%) Late mortality 3 (15%) 6 (30%) 0.13 CPB, cardiopulmonary bypass.
4 45 P.S. Risteski et al. / Interactive CardioVascular and Thoracic Surgery 8 (009) Fig. 1. Hemodynamic results. (a) Mean transvalvular gradients. (b) Mean effective orifice area. (c) Left ventricular ejection fraction. (d) Left ventricular mass index. At five years after the operation, we have witnessed a significant regression of left ventricular mass, achieved by both prostheses, without significant differences in the rate and completeness of this regression between the groups. In addition, no significant differences in the hemodynamic performance and postoperative left ventricular function were observed. Survival of the patients was not related to the nature of the biologic valve. The slope of the observed rate of regression of left ventricular mass was steepest during the first 6 months after the operation, and continued thereafter in the first 1 months although with somewhat less impact, only to remain nearly unchanged at mid-term. Although the myocardial cellular hypertrophy as well as the myocardial collagen fibrosis may take more than a year to regress after the AVR w11x, it seems that one year of follow-up may suffice to assess the impact of the valve substitute upon the regression of the LVH. Others have come to the same conclusion w6, 1x. The incomplete regression of left ventricular mass at midterm observed in both groups only confirms the inevitable influence of other factors like age, hypertension and gender upon this process. Since all these factors did not differ between the groups, they could not have influenced the outcomes. Over the years of follow-up, the transvalvular gradients have not displayed any clinically relevant or significant difference between the groups. We chose to assess the mean and not peak transvalvular gradients in our study since they better correlate with the left ventricular hypertrophy. Peak gradients are more factor-related and display large variations with physical exertion which on the other hand is rarely observed in a population of patients in their eight or ninth decade, like those subjected in this study. Other prospective randomized studies that emerged in the meantime have come to the same conclusion. Ali and co-workers have randomized 161 patients to receive a stented or stentless aortic valve substitute, and found neither statistically nor clinically relevant difference in the mean transvalvular gradients as well as the regression of the LV mass w13x. The ASSERT investigators concordantly concluded no difference in LV mass regression at both 6 and 1 months after replacement of the aortic valve with a stentless or stented valve substitute in 00 patients w14x. The study conducted by Walther et al., however, did show differences in peak gradients and LV mass index at 6 months after the operation w15x. They postulate that a difference of 3.4 mmhg in peak gradients is accountable for the reduced LV mass regression in the stentled valve group. Mean gradients have not been reported in their study. Worthy of mention is that they did, however, compare a stentless valve with a first-generation stented valve, the Carpentier Edwards porcine valve. However, this cause and effect relationship with the lower peak gradients was lost at mid-term follow-up w16x. Marquez and colleagues have tested the hydrodynamic performance of six commercially available bioprosthetic valves with various sizes in vitro at various flow rates w17x. Considerable differences in pressure gradients have been found among tested valves at each size. The Carpentier Edwards Perimount valve showed superior performance at all sizes tested including lowest gradients compared to the other valve substitutes for each size. Clearly, no patientrelated factors could have influenced the hydrodynamic performance of each valve in vitro. This prosthetic valve (Carpentier Edwards Perimount) has only recently been compared in vivo to another stentless substitute (Toronto stentless porcine valve) on a group of patients somewhat
5 P.S. Risteski et al. / Interactive CardioVascular and Thoracic Surgery 8 (009) younger than that investigated in this study w18x. They report of no significant differences in hemodynamic function or clinical events between both biologic valves neither in the early postoperative period nor at 5 years. To our surprise, we could not support previously reported findings, which showed faster and more complete regression of LV-hypertrophy as well as superior hemodynamics of stentless valves over stented bioprostheses. One of the possible explanations may be that those reports studied mainly first-generation stented aortic bioprostheses w15x. Modern bioprosthetic valves have been shown to have excellent hemodynamic performance w16, 19x and this may account for the equally good performance as seen with the stentless valves. As no significant differences in transvalvular gradients were detected in this study, it is not surprising that no differences in the rate and completeness of LV mass regression resulted. Overall, the complexity of stentless valve implantation with its prolonged cross-clamping times might not be justifiable under these circumstances, if as we found, the same results can be achieved with a standard stented bioprosthesis. Our results are in concordance with the major prospective randomized studies that emerged in the meantime w13, 14, 18x. References w1x David TE, Ivanov J, Armstrong S, Feindel CM, Cohen G. Late results of heart valve replacement with the Hancock II bioprosthesis. J Thorac Cardiovasc Surg 001;11: wx Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus bioprosthetic valve: final report of the Veterans Affairs randomised trial. J Am Coll Cardiol 000;36: w3x Jamieson WR, Burr LH, Tyers GF, Munro AI. Carpentier-Edwards standard and supraannular porcine bioprosthesis: 10 year comparision of structural valve deterioration. J Heart Valve Dis 1994;3: w4x Rossi A, Tomaino M, Golia G, Anselmi M, Fuca G, Zardini P. Echocardiographic prediction of clinical outcome in medically treated patients with aortic stenosis. Am Heart J 000;140: w5x Levy D. Clinical significance of left ventricular hypertrophy: insights from the Framingham Study. J Cardiovasc Pharmacol 1991;17(Suppl ): S1 S. w6x Jin XY, Zhang ZM, Gibson DG, Yacoub MH, Pepper JR. Effects of valve substitute on changes in left ventricular function and hypertrophy after aortic valve replacement. Ann Thorac Surg 1996;6: w7x Thomson HL, O Brian MF, Almeida AA, Tesar PJ, Davison MB, Burstow DJ. Haemodynamics and left ventricular mass regression: a comparision of the stentless, stented and mechanical sortic valve replacement. Eur J Cardiothorac Surg 1998;13: w8x Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977;55: w9x Del Rizzo DF, Abdoh A, Cartier P, Doty D, Westaby S. Factors affecting left ventricular mass regression after aortic valve replacement with stentless valves. Semin Thorac Cardiovasc Surg 1999;8: w10x Doss M, Martens S, Wood JP, Aybek T, Kleine P, Wimmer Greinecker G, Moritz A. Performance of stentless versus stented aortic valve bioprostheses in the elderly patient: a prospective randomized trial. Eur J Cardiothorac Surg 003;3: w11x Krayenbuehl HP, Hess OM, Monrad ES, Schneider JS, Mall G, Turina M. Left ventricular myocardial structure in aortic valve disease before, immediately, and late after aortic valve replacement. Circulation 1989;79: w1x De Paulis R, Sommariva L, Colagrande L, De Matteis GM, Fratini S, Tomai F, Bassano C, Penta de Peppo A, Chiariello L. Regression of left ventricular hypertrophy after aortic valve replacement for aortic stenosis with different valve substitutes. J Thorac Cardiovasc Surg 1998;116:590. w13x Ali A, Halstead JC, Cafferty F, Sharples L, Rose F, Lee E, Rusk R, Dunning J, Argano V, Tsui S. Early clinical and hemodynamic outcomes after stented and stentless aortic valve replacement: results from a randomised controlled trial. Ann Thorac Surg 007;83: w14x Perez de Arenaza D, Lees B, Flather M, Nugara F, Husebye T, Jasinski M, Cisowski M, Khan M, Henein M, Gaer J, Guvendik L, Bochenek A, Wos S, Lie M, Van Nooten G, Pennell D, Pepper J; ASSERT (Aortic Stentless versus Stented valve assessed by Echocardiography Randomized Trial) Investigators. Randomised comparison of stentless versus stented valves for aortic stenosis: effects on left ventricular mass. Circulation 005;11: w15x Walther T, Falk V, Langebartels G, Krüger M, Bernhardt U, Diegeler A, Gummert J, Autschbach R, Mohr FW. Prospectively randomised evaluation of stentless versus conventional biological aortic valves. Circulation 1999;100(Suppl II):II-6 II-10. w16x Lehmann S, Walther T, Kempfert J, Leontjev S, Rastan A, Falk V, Mohr FW. Stentless versus conventional xenograft aortic valve replacement: midterm results of a prospectively randomized trial. Ann Thorac Surg 007;84: w17x Marquez S, Hon RT, Yoganathan AP. Comparative hydrodynamic evaluation of bioprosthetic heart valves. J Heart Valve Dis 001;10: w18x Chambers JB, Rimington HM, Hodson F, Rajani R, Blauth CI. The subcoronary Toronto stentless versus supra-annular Perimount stented replacement aortic valve: early clinical and hemodynamic results of a randomized comparison in 160 patients. J Thorac Cardiovasc Surg 006; 131: w19x Dellgren G, David TE, Raanani E, Armstrong S, Ivanov J, Rakowski H. Late hemodynamic and clinical outcomes of aortic valve replacement with the Carpentier-Edwards Perimount pericardial bioprosthesis. J Thorac Cardiovasc Surg 00;14:
Management of Difficult Aortic Root, Old and New solutions
Management of Difficult Aortic Root, Old and New solutions Hani K. Najm MD, Msc, FRCSC,, FACC, FESC Chairman, Pediatric and Congenital Heart Surgery Cleveland Clinic Conflict of Interest None Difficult
More informationPPM: How to fit a big valve in a small heart
PPM: How to fit a big valve in a small heart Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC King Abdulaziz Cardiac Centre National Guard Health Affairs Riyadh, Saudi Arabia GHA meeting Muscat
More informationREGRESSION OF LEFT VENTRICULAR HYPERTROPHY AFTER AORTIC VALVE REPLACEMENT FOR AORTIC STENOSIS WITH DIFFERENT VALVE SUBSTITUTES
REGRESSION OF LEFT VENTRICULAR HYPERTROPHY AFTER AORTIC VALVE REPLACEMENT FOR AORTIC STENOSIS WITH DIFFERENT VALVE SUBSTITUTES Ruggero De Paulis, MD Luigi Sommariva, MD Luisa Colagrande, MD Giovanni Maria
More informationThe stentless bioprosthesis has many salient features that
Aortic Valve Replacement with the Medtronic Freestyle Xenograft Using the Subcoronary Implantation Technique D. Michael Deeb, MD The stentless bioprosthesis has many salient features that make it an attractive
More informationExperience with 500 Stentless Aortic Valve Replacements
Experience with 500 Stentless Aortic Valve Replacements Dimitrios C. Iliopoulos, MD Cardiac Surgeon Ass. Professor of Surgery University of Athens, School of Medicine I declare no conflict of interest
More informationTSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD
TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationEight-Year Results of Aortic Root Replacement With the Freestyle Stentless Porcine Aortic Root Bioprosthesis
Eight-Year Results of Aortic Root Replacement With the Freestyle Stentless Porcine Aortic Root Bioprosthesis Neal D. Kon, MD,* Robert D. Riley, MD, Sandy M. Adair, RN, Dalane W. Kitzman, MD, and A. Robert
More informationEleven years experience with the Biocor stentless aortic bioprosthesis: clinical and hemodynamic follow-up with long-term relative survival rate
European Journal of Cardio-thoracic Surgery 22 (2002) 912 921 www.elsevier.com/locate/ejcts Eleven years experience with the Biocor stentless aortic bioprosthesis: clinical and hemodynamic follow-up with
More informationBicuspid aortic root spared during ascending aorta surgery: an update of long-term results
Short Communication Bicuspid aortic root spared during ascending aorta surgery: an update of long-term results Marco Russo, Guglielmo Saitto, Paolo Nardi, Fabio Bertoldo, Carlo Bassano, Antonio Scafuri,
More informationSingle-center experience using the Freedom SOLO aortic bioprosthesis
Single-center experience using the Freedom SOLO aortic bioprosthesis Dimitrios C. Iliopoulos, MD, a,b,c Aris Rezar Deveja, MD, b Vasiliki Androutsopoulou, MD, b Vasilios Filias, MD, b Eleftherios Kastelanos,
More information15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses
ORIGINAL CONTRIBUTION 15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses WR Eric Jamieson, MD, Eva Germann, MSc, Michel R Aupart, MD 1, Paul H Neville, MD 1, Michel A Marchand,
More informationCarpentier-Edwards Pericardial Valve in the Aortic Position: 25-Years Experience
SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://www.annalsthoracicsurgery.org/cme/ home. To take the CME activity related to this article, you must have either an STS member
More informationReconstruction of the intervalvular fibrous body during aortic and
Aortic and mitral valve replacement with reconstruction of the intervalvular fibrous body: An analysis of clinical outcomes Nilto C. De Oliveira, MD Tirone E. David, MD Susan Armstrong, MSc Joan Ivanov,
More informationA Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision
A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction
More informationAortic valve replacement with the Sorin Pericarbon Freedom stentless prosthesis: 7 years experience in 130 patients
Aortic valve replacement with the Sorin Pericarbon Freedom stentless prosthesis: 7 years experience in 130 patients Augusto D Onofrio, MD, Stefano Auriemma, MD, Paolo Magagna, MD, Alessandro Favaro, MD,
More informationReoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment
Reoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment W.R.E. Jamieson, MD; L.H. Burr, MD; R.T. Miyagishima, MD; M.T. Janusz, MD; G.J. Fradet, MD; S.V. Lichtenstein, MD; H. Ling, MD Background
More informationHani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz
Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia Decision process for
More informationLong-term results (22 years) of the Ross Operation a single institutional experience
Long-term results (22 years) of the Ross Operation a single institutional experience Authors: Costa FDA, Schnorr GM, Veloso M,Calixto A, Colatusso D, Balbi EM, Torres R, Ferreira ADA, Colatusso C Department
More informationTAVR for Valve-In-Valve. Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology
TAVR for Valve-In-Valve Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology Temple Hearth and Vascular Institute Disclosures: Consultant: Cardiac Assist TAVR for
More informationThe St. Jude Medical Biocor Bioprosthesis
The St. Jude Medical Biocor Bioprosthesis Clinical Evidence of Long-term Durability Long-term Biocor Experience A Review and Comparative Assessment Long-term Biocor Stented Tissue Valve Studies Twenty-year
More information16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900
CLINICAL COMMUNIQUé 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 69 The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 69, was introduced into clinical
More informationNew Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor. Cardiothoracic Radiology
New Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor Cardiothoracic Radiology Disclosure I have no disclosure pertinent to this presentation.
More informationValve prosthesis-patient mismatch (PPM) was first defined
Impact of Valve Prosthesis-Patient Mismatch on Short-Term Mortality After Aortic Valve Replacement Claudia Blais, BSc; Jean G. Dumesnil, MD; Richard Baillot, MD; Serge Simard, MS; Daniel Doyle, MD; Philippe
More informationRegression of Hypertrophy After Carpentier-Edwards Pericardial Aortic Valve Replacement
Regression of Hypertrophy After Carpentier-Edwards Pericardial Aortic Valve Replacement Steven S. Khan, MD, Robert J. Siegel, MD, Michele A. DeRobertis, RN, Carlos E. Blanche, MD, Robert M. Kass, MD, Wen
More informationHemodynamics Benefit of Supra-Annular Design in Failed Bio-Prosthetic Valves
Hemodynamics Benefit of Supra-Annular Design in Failed Bio-Prosthetic Valves Speaker's name: I have the following potential conflicts of interest to report: Proctorship for Medtronic Agenda Failure modes
More informationThe operative mortality rate after redo valvular operations
Clinical Outcomes of Redo Valvular Operations: A 20-Year Experience Naoto Fukunaga, MD, Yukikatsu Okada, MD, Yasunobu Konishi, MD, Takashi Murashita, MD, Mitsuru Yuzaki, MD, Yu Shomura, MD, Hiroshi Fujiwara,
More informationOutcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease
Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease TIRONE E. DAVID, MD ; SEMIN THORAC CARDIOVASC SURG 19:116-120c 2007 ELSEVIER INC. PRESENTED BY INTERN 許士盟 Mitral valve
More informationStentless aortic xenografts were introduced a decade
Survival After Stentless and Stented Xenograft Aortic Valve Replacement: A Concurrent, Controlled Trial Giovanni Battista Luciani, MD, Gianluca Casali, MD, Stefano Auriemma, MD, Francesco Santini, MD,
More informationLong-term mortality is increased in patients after aortic valve replacement
Bakhtiary et al Surgery for Acquired Cardiovascular Disease Stentless bioprostheses improve postoperative coronary flow more than stented prostheses after valve replacement for aortic stenosis Farhad Bakhtiary,
More informationMedium-Term Determinants of Left Ventricular Mass Index After Stentless Aortic Valve Replacement
Medium-Term Determinants of Left Ventricular Mass Index After Stentless Aortic Valve Replacement Xu Y. Jin, MD, PhD, Ravi Pillai, FRCS, and Stephen Westaby, FRCS Department of Cardiac Surgery, Oxford Heart
More informationAortic stenosis is the most common acquired heart valve. The Toronto Root Bioprosthesis: Midterm Results in 186 Patients
The Toronto Root Bioprosthesis: Midterm Results in 186 Patients Sven Lehmann, MD, Thomas Walther, MD, PhD, Sergey Leontyev, MD, Jörg Kempfert, MD, Jens Garbade, MD, Michael A. Borger, MD, PhD, and Friedrich
More informationHani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia.
Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia. Decision process for Management of any valve Timing Feasibility
More informationCLINICAL COMMUNIQUE 16 YEAR RESULTS
CLINICAL COMMUNIQUE 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 Introduction The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 6900, was introduced
More informationReoperations after primary aortic valve replacement
Third-Time Aortic Valve Replacement: Patient s and Operative Outcome Kasra Shaikhrezai, MD, MRCS, Giordano Tasca, MD, FETCS, Mohamed Amrani, PhD, FETCS, Gilles Dreyfus, MD, FETCS, and George Asimakopoulos,
More informationCase. 15-year-old boy with bicuspid AV Severe AR with moderate AS. Ross vs. AVR (or AVP)
Case 15-year-old boy with bicuspid AV Severe AR with moderate AS Ross vs. AVR (or AVP) AMC case 14-year-old boy with bicuspid AV Severe AS with mild AR Body size Bwt: 55 kg, Ht: 154 cm, BSA: 1.53 m 2 Echocardiography
More informationThe diameter of the aortic valve is in direct proportion
The CarboMedics Top-Hat Supraannular Prosthesis José M. Bernal, MD, Rafael Martin-Duran, MD, José M. Rabasa, MD, and José M. Revuelta, MD Departments of Cardiovascular Surgery and Echocardiography, Hospital
More informationOutcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison
Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison Mauri, V. et al.: Circ Cardiovasc Interv. 2017;10:e005013 All trademarks are the property
More informationPROVEN PLUS. Introducing the Avalus Aortic Valve by Medtronic.
PROVEN PLUS. Introducing the Avalus Aortic Valve by Medtronic. With more than 40 years of heart valve innovations, we took proven valve design concepts and adapted them for excellent implantability for
More informationT sors in the following aspects: the porcine aortic valve
Clinical and Hemodynamic Assessment of the Hancock I1 Bioprosthesis Tirone E. David, MD, Susan Armstrong, MSc, and Zhao Sun, MA Division of Cardiovascular Surgery, The Toronto Hospital and University of
More informationStentless aortic valves. Current aspects
Endorsed by proceedings in Intensive Care Cardiovascular Anesthesia EXPERT OPINION HSR Proceedings in Intensive Care and Cardiovascular Anesthesia 2012; 4(2): 77-82 Stentless aortic valves. Current aspects
More informationThe increasing number of elderly patients with complex
Valved Stentless Composite Graft: Clinical Outcomes and Hemodynamic Characteristics Paul P. Urbanski, MD, Anno Diegeler, MD, Alexander Siebel, MD, Michael Zacher, MD, and Robert W. Hacker, MD Herz- und
More informationPresenter Disclosure. Patrick O. Myers, M.D. No Relationships to Disclose
Presenter Disclosure Patrick O. Myers, M.D. No Relationships to Disclose Aortic Valve Repair by Cusp Extension for Rheumatic Aortic Insufficiency in Children Long term Results and Impact of Extension Material
More informationThe Ross Procedure: Outcomes at 20 Years
The Ross Procedure: Outcomes at 20 Years Tirone David Carolyn David Anna Woo Cedric Manlhiot University of Toronto Conflict of Interest None The Ross Procedure 1990 to 2004 212 patients: 66% 34% Mean age:
More informationA 20-year experience of 1712 patients with the Biocor porcine bioprosthesis
Acquired Cardiovascular Disease Mykén and Bech-Hansen A 2-year experience of 1712 patients with the Biocor porcine bioprosthesis Pia S. U. Mykén, MD, PhD, a and Odd Bech-Hansen, MD, PhD b Objective: The
More informationCopyright by ICR Publishers 2014
Comprehensive Hemodynamic Performance and Frequency of Patient-Prosthesis Mismatch of the St. Jude Medical Trifecta Bioprosthetic Aortic Valve Ajay Yadlapati 1, Jimmy Diep 3, Mary-Jo Barnes 2, Tristan
More informationAn anterior aortoventriculoplasty, known as the Konno-
The Konno-Rastan Procedure for Anterior Aortic Annular Enlargement Mark E. Roeser, MD An anterior aortoventriculoplasty, known as the Konno-Rastan procedure, is a useful tool for the cardiac surgeon. Originally,
More informationThe implantation of bioprostheses is the preferred. Influence of Prosthesis Patient Mismatch on Diastolic Heart Failure After Aortic Valve Replacement
Influence of Prosthesis Patient Mismatch on Diastolic Heart Failure After Aortic Valve Replacement Shahab Nozohoor, MD, Johan Nilsson, MD, PhD, Carsten Lührs, MD, Anders Roijer, MD, PhD, and Johan Sjögren,
More informationAortic valve repair: Techniques and Pitfalls. Allan Stewart, MD Columbia University Medical Center New York, NY
Aortic valve repair: Techniques and Pitfalls Allan Stewart, MD Columbia University Medical Center New York, NY Take Away Points 1. Valve anatomy is essential to assess repair 2. Unique Decisions with Aneurysm/AI
More informationCoreValve in a Degenerative Surgical Valve
CoreValve in a Degenerative Surgical Valve Ran Kornowski, MD, FESC, FACC Chairman Department of Cardiology Rabin Medical Center, Petach Tikva, Israel Disclosure Statement of Financial Interest I, Ran Kornowski,
More informationReverse left atrium and left ventricle remodeling after aortic valve interventions
Reverse left atrium and left ventricle remodeling after aortic valve interventions Alexandra Gonçalves, Cristina Gavina, Carlos Almeria, Pedro Marcos-Alberca, Gisela Feltes, Rosanna Hernández-Antolín,
More informationClinical material and methods. Copyright by ICR Publishers 2003
Fourteen Years Experience with the CarboMedics Valve in Young Adults with Aortic Valve Disease Jan Aagaard 1, Jens Tingleff 2, Per V. Andersen 1, Christel N. Hansen 2 1 Department of Cardio-Thoracic and
More informationHemodynamic performance of the Medtronic Mosaic and Perimount Magna aortic bioprostheses: five-year results of a prospectively randomized study
European Journal of Cardio-thoracic Surgery 39 (2011) 844 852 www.elsevier.com/locate/ejcts Hemodynamic performance of the Medtronic Mosaic and Perimount Magna aortic bioprostheses: five-year results of
More informationPROSTHETIC VALVE BOARD REVIEW
PROSTHETIC VALVE BOARD REVIEW The correct answer D This two chamber view shows a porcine mitral prosthesis with the typical appearance of the struts although the leaflets are not well seen. The valve
More informationTissue vs Mechanical What s the Data??
Biological (Tissue) Valve in a 60 year old patient: Debate Tissue vs Mechanical What s the Data?? Joseph E. Bavaria, MD Immediate-Past President - Society of Thoracic Surgeons (STS) Brooke Roberts-William
More informationThe impact of prosthesis patient mismatch after aortic valve replacement varies according to age at operation
Editor s choice Scan to access more free content 1 Division of Cardiac Surgery, The Johns Hopkins Hospital, Baltimore, Maryland, USA 2 Division of Cardiac Surgery, University of Ottawa Heart Institute,
More informationExpanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?
Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? RM Suri, V Sharma, JA Dearani, HM Burkhart, RC Daly, LD Joyce, HV Schaff Division of Cardiovascular Surgery, Mayo Clinic, Rochester,
More informationRepeated mitral valve replacement in a patient with extensive annular calcification
CASE REPORT Open Access Repeated mitral valve replacement in a patient with extensive annular calcification Tadashi Kitamura 1,2*, Sachito Fukuda 1, Takahiro Sawada 1, Sumio Miura 1, Ikutaro Kigawa 1,3
More informationAortic Valve Replacement or Heart Transplantation in Patients With Aortic Stenosis and Severe Left Ventricular Dysfunction
Aortic Valve Replacement or Heart Transplantation in Patients With Aortic Stenosis and Severe Left Ventricular Dysfunction L.S.C. Czer, S. Goland, H.J. Soukiasian, S. Gallagher, M.A. De Robertis, J. Mirocha,
More informationDepartment of Cardiothoracic Surgery, Heart and Lung Center, Lund University Hospital, Lund, Sweden
Long-Term Outcome of the Mitroflow Pericardial Bioprosthesis in the Elderly after Aortic Valve Replacement Johan Sjögren, Tomas Gudbjartsson, Lars I. Thulin Department of Cardiothoracic Surgery, Heart
More informationThe Edge-to-Edge Technique f For Barlow's Disease
The Edge-to-Edge Technique f For Barlow's Disease Ottavio Alfieri, Michele De Bonis, Elisabetta Lapenna, Francesco Maisano, Lucia Torracca, Giovanni La Canna. Department of Cardiac Surgery, San Raffaele
More informationAortic valve replacement in predominant aortic stenosis: What is an appropriate size valve?
IJTCVS Joshi et al 141 Aortic valve replacement in predominant aortic stenosis: What is an appropriate size valve? Kishore Joshi, M.Ch., Sachin Talwar, M.Ch., Devagourou Velayoudham, M.Ch., Arkalgud Sampath
More informationProsthetic valve dysfunction: stenosis or regurgitation
Prosthetic valve dysfunction: stenosis or regurgitation Jean G. Dumesnil MD, FRCP(C), FACC, FASE(Hon) Quebec Heart and Lung Institute, Québec, Québec No disclosures Possible Causes of High Gradients in
More informationORIGINAL PAPER. The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
Nagoya J. Med. Sci. 78. 369 ~ 376, 2016 doi:10.18999/nagjms.78.4.369 ORIGINAL PAPER The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
More informationHow to Avoid Prosthesis-Patient Mismatch
How to Avoid Prosthesis-Patient Mismatch Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE, FESC Canada Research Chair in Valvular Heart Diseases INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE DE QUÉBEC
More informationInfluence of patient gender on mortality after aortic valve replacement for aortic stenosis
Influence of patient gender on mortality after aortic valve replacement for aortic stenosis Jennifer Higgins, MD, W. R. Eric Jamieson, MD, Osama Benhameid, MD, Jian Ye, MD, Anson Cheung, MD, Peter Skarsgard,
More informationPatient/prosthesis mismatch: how to evaluate and when to act?
Patient/prosthesis mismatch: how to evaluate and when to act? Svend Aakhus, MD, PhD Oslo University Hospital, Norway Disclosures: No conflict of interest Types of aortic valve prostheses (AVR) Mechanical
More informationTHE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT
THE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT Gideon Cohen, MD Tirone E. David, MD Joan Ivanov, MSc Sue Armstrong, MSc
More informationEchocardiographic Evaluation of Mitral Valve Prostheses
Echocardiographic Evaluation of Mitral Valve Prostheses Dennis A. Tighe, M.D., FACC, FACP, FASE Cardiovascular Medicine University of Massachusetts Medical School Worcester, MA www.asecho.org 1 Nishimura
More informationProf. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM
The Patient with Aortic Stenosis and Mitral Regurgitation Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM Aortic Stenosis + Mitral Regurgitation?
More informationIncidence of prosthesis-patient mismatch in patients receiving mitral Biocor porcine prosthetic valves
INTERVENTION/VALVULAR HEART DISEASE ORIGINAL ARTICLE Cardiology Journal 2016, Vol. 23, No. 2, 178 183 DOI: 10.5603/CJ.a2016.0011 Copyright 2016 Via Medica ISSN 1897 5593 Incidence of prosthesis-patient
More information42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim
42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim Current Guideline for AR s/p TOF Surgery is reasonable in adults with prior repair of
More informationValve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal
Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection
More informationMechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute
Mechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute Assistant Professor, Georgetown School of Medicine
More informationUse of Stentless Xenografts in the Aortic Position: Determinants of Early and Late Outcome
Use of Stentless Xenografts in the Aortic Position: Determinants of Early and Late Outcome A. Ruchan Akar, MD, Adam Szafranek, MD, Christos Alexiou, FRCS, Robert Janas, MD, Marek J. Jasinski, MD, Justiaan
More informationMedtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance
Medtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance W. R. Eric Jamieson, MD, a Friedrich-Christian Riess, MD, b Peter J. Raudkivi, MD, c Jacques Metras, MD, d Edward F. G. Busse,
More informationChoice of Prosthetic Heart Valve in Adults
Journal of the American College of Cardiology Vol. 55, No. 22, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.085
More informationCarpentier-Edwards supra-annular aortic porcine bioprosthesis: Clinical performance over 20 years
Surgery for Acquired Cardiovascular Disease Carpentier-Edwards supra-annular aortic porcine bioprosthesis: Clinical performance over 20 years W. R. Eric Jamieson, MD, Lawrence H. Burr, MD, Robert T. Miyagishima,
More informationIndications and Late Results of Aortic Valve Repair
Indications and Late Results of Aortic Valve Repair Prof. Gebrine El Khoury Department of Cardiovascular and Thoracic Surgery Cliniques St. Luc Brussels, Belgium Aortic Valve Repair Question # 1 Can the
More informationAnnular Stabilization Techniques in the Context of Aortic Valve Repair
Annular Stabilization Techniques in the Context of Aortic Valve Repair Prashanth Vallabhajosyula, MD MS University of Pennsylvania, Philadelphia, Pennsylvania 2 nd North American Aortic Valve Repair Symposium
More informationHow to Perform a Valve Sparing Root Replacement Joseph S. Coselli, M.D.
How to Perform a Valve Sparing Root Replacement Joseph S. Coselli, M.D. AATS International Cardiovascular Symposium 2017 Session 6: Technical Aspects of Open Surgery on the Aortic Valve Sao Paulo, Brazil
More informationStainless Steel. Cobalt-chromium
Sapien is better than Corevalve! Raj R. Makkar, MD Associate Director, Cedars-Sinai Heart Institute Associate Professor, UCLA School of Medicine, Los Angeles Eberhard Grube: Pioneer in the field of TAVR
More informationPatient prosthesis mismatch after mitral valve replacement: Myth or reality?
Patient prosthesis mismatch after mitral valve replacement: Myth or reality? Pasquale Totaro, MD, a and Vincenzo Argano, MD b Objective: Determining the risk of patient prosthesis mismatch after mitral
More informationStentless aortic valve replacement in the young patient: long-term results
Christ et al. Journal of Cardiothoracic Surgery 2013, 8:68 RESEARCH ARTICLE Open Access Stentless aortic valve replacement in the young patient: long-term results Torsten Christ *, Herko Grubitzsch, Benjamin
More informationW e have previously reported the results of a randomised
715 CARDIOVASCULAR MEDICINE Twenty year comparison of a mechanical heart valve with porcine bioprostheses H Oxenham, P Bloomfield, D J Wheatley, R J Lee, J Cunningham, R J Prescott, H C Miller... See end
More informationAortic valve replacement: is porcine or bovine valve better?
Interactive CardioVascular and Thoracic Surgery Advance Access published December 4, 2012 Interactive CardioVascular and Thoracic Surgery (2012) 1 13 doi:10.1093/icvts/ivs447 BEST EVIDENCE TOPIC Aortic
More informationEffect of Valve Suture Technique on Incidence of Paraprosthetic Regurgitation and 10-Year Survival
Effect of Valve Suture Technique on Incidence of Paraprosthetic Regurgitation and 10-Year Survival Sukumaran K. Nair, FRCS (C Th), Gauraang Bhatnagar, MBBS, Oswaldo Valencia, MD, and Venkatachalam Chandrasekaran,
More informationLate secondary TR after left sided heart disease correction: is it predictibale and preventable
Late secondary TR after left sided heart disease correction: is it predictibale and preventable Gilles D. Dreyfus Professor of Cardiothoracic surgery Nath J, et al. JACC 2004 PREDICT Incidence of secondary
More informationRepair or Replacement
Surgical intervention post MitraClip Device: Repair or Replacement Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationAortic Valve Replacement With 17-mm Mechanical Prostheses: Is Patient Prosthesis Mismatch a Relevant Phenomenon?
Aortic Valve Replacement With 17-mm Mechanical Prostheses: Is Patient Prosthesis Mismatch a Relevant Phenomenon? Andrea Garatti, MD, Francesca Mori, MD, Francesco Innocente, MD, Alberto Canziani, MD, Piervincenzo
More informationReplacement of the mitral valve in the presence of
Mitral Valve Replacement in Patients with Mitral Annulus Abscess Christopher M. Feindel Replacement of the mitral valve in the presence of an abscess of the mitral annulus presents a major challenge to
More informationEulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain
Eulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain Device Landscape 2010 PERCUTANEOUS TECHNIQUES Percutaneous indirect annuloplasty Percutaneous direct annuloplasty Edge to Edge ( E-Valve ) Non
More informationMid-term results in patients having tricuspidization of the quadricuspid aortic valve
Song et al. Journal of Cardiothoracic Surgery 2014, 9:29 RESEARCH ARTICLE Open Access Mid-term results in patients having tricuspidization of the quadricuspid aortic valve Meong Gun Song 1, Hyun Suk Yang
More informationImpact of Valve Prosthesis-Patient Mismatch on Left Ventricular Mass Regression Following Aortic Valve Replacement
Impact of Valve Prosthesis-Patient Mismatch on Left Ventricular Mass Regression Following Aortic Valve Replacement Giordano Tasca, MD, Federico Brunelli, MD, Marco Cirillo, MD, Margherita DallaTomba, MD,
More informationLate failure of transcatheter heart valves: An open question
Late failure of transcatheter heart valves: An open question A comparison with surgically implanted bioprosthetic heart valves. A. Rashid The Cardiothoracic Centre Liverpool, UK. Conflict of Interest Statement
More informationTranscatheter aortic valves in aortic regurgitation Gry Dahle Dept of Cardiothoracic- and vascular surgery Rikshospitalet, Oslo University Hospital,
Transcatheter aortic valves in aortic regurgitation Gry Dahle Dept of Cardiothoracic- and vascular surgery Rikshospitalet, Oslo University Hospital, Oslo, Norway Aortic regurgitation Prevalence in Framingham
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/28521 holds various files of this Leiden University dissertation Author: Katsanos, Spyridon Title: Outcomes of transcatheter aortic valve implantation Issue
More informationAortic valve repair is an accepted option for aortic valve
Complex Aortic Valve Disease in Children Christopher W. Baird, MD,* and Pedro J. del Nido, MD Aortic valve repair is an accepted option for aortic valve pathologic conditions in children and young adults.
More informationPulmonary Valve Replacement
Pulmonary Valve Replacement Christian Kreutzer MD Hospital Nacional Alejandro Posadas Hospital Universitario Austral (No disclosures) Scope of the problem. CHD with PS or PA require a RVOT procedure. Tetralogy
More informationLeft Ventricular Mass Regression Early After Aortic Valve Replacement
Left Ventricular Mass Regression Early After Aortic Valve Replacement George T. Christakis, MD, Campbell D. Joyner, MD, Christopher D. Morgan, MD, Stephen E. Fremes, MD, Karen J. Buth, MSc, Jeri Y. Sever,
More information